Cargando…

Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells

Immune checkpoint inhibition has been shown to successfully reactivate endogenous T cell responses directed against tumor-associated antigens, resulting in significantly prolonged overall survival in patients with various tumor entities. For malignancies with low endogenous immune responses, this ap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lichtenegger, Felix S., Rothe, Maurine, Schnorfeil, Frauke M., Deiser, Katrin, Krupka, Christina, Augsberger, Christian, Schlüter, Miriam, Neitz, Julia, Subklewe, Marion
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835137/ https://www.ncbi.nlm.nih.gov/pubmed/29535740 http://dx.doi.org/10.3389/fimmu.2018.00385

Ejemplares similares

T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment
por: Schnorfeil, Frauke M., et al.
Publicado: (2015)

Toll‐like receptor 7/8‐matured RNA‐transduced dendritic cells as post‐remission therapy in acute myeloid leukaemia: results of a phase I trial
por: Lichtenegger, Felix S, et al.
Publicado: (2020)

Fusion of Bacterial Flagellin to a Dendritic Cell-Targeting αCD40 Antibody Construct Coupled With Viral or Leukemia-Specific Antigens Enhances Dendritic Cell Maturation and Activates Peptide-Responsive T Cells
por: Schmitt, Saskia, et al.
Publicado: (2020)

P20. Lack of T cell exhaustion in acute myeloid leukaemia
por: Schnorfeil, FM, et al.
Publicado: (2014)

Recent developments in immunotherapy of acute myeloid leukemia
por: Lichtenegger, Felix S., et al.
Publicado: (2017)

Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
por: Haubner, S., et al.
Publicado: (2018)

Next-generation dendritic cells for immunotherapy of acute myeloid leukemia
por: Schnorfeil, Frauke, et al.
Publicado: (2014)

Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
por: Köhnke, Thomas, et al.
Publicado: (2015)

Blood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigens
por: Hänel, Gerulf, et al.
Publicado: (2021)

PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy
por: Shi, Ning, et al.
Publicado: (2022)

Blockade of PD-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells
por: Ma, Jiajia, et al.
Publicado: (2023)

Interferon-γ Receptor Signaling in Dendritic Cells Restrains Spontaneous Proliferation of CD4(+) T Cells in Chronic Lymphopenic Mice
por: Knop, Laura, et al.
Publicado: (2019)

Toward an indoor lighting solution for social jet lag
por: Neitz, Alex, et al.
Publicado: (2023)

Different Expression Characteristics of LAG3 and PD-1 in Sepsis and Their Synergistic Effect on T Cell Exhaustion: A New Strategy for Immune Checkpoint Blockade
por: Niu, Bailin, et al.
Publicado: (2019)

ScanLag: High-throughput Quantification of Colony Growth and Lag Time
por: Levin-Reisman, Irit, et al.
Publicado: (2014)

PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma
por: Zhong, Yu-Min, et al.
Publicado: (2022)

Recalling the Biological Significance of Immune Checkpoints on NK Cells: A Chance to Overcome LAG3, PD1, and CTLA4 Inhibitory Pathways by Adoptive NK Cell Transfer?
por: Lanuza, Pilar M., et al.
Publicado: (2020)

CD86 and IL-12p70 Are Key Players for T Helper 1 Polarization and Natural Killer Cell Activation by Toll-Like Receptor-Induced Dendritic Cells
por: Lichtenegger, Felix S., et al.
Publicado: (2012)

Triple-Negative Breast Cancer: Intact Mismatch Repair and Partial Co-Expression of PD-L1 and LAG-3
por: Wu, Shafei, et al.
Publicado: (2021)

Diminished LAG3(+) B cells correlate with exacerbated rheumatoid arthritis
por: Hu, Suiyuan, et al.
Publicado: (2023)

PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors
por: Wang, Jaeyun Jane, et al.
Publicado: (2019)

Blockade of LAG-3 in PD-L1-Deficient Mice Enhances Clearance of Blood Stage Malaria Independent of Humoral Responses
por: Furtado, Raquel, et al.
Publicado: (2021)

LAG3’s Enigmatic Mechanism of Action
por: Graydon, Colin G., et al.
Publicado: (2021)

The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression
por: Rohrbacher, Lisa, et al.
Publicado: (2021)

Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission
por: Beck, Barbara, et al.
Publicado: (2011)

Self-Antigen Presentation by Dendritic Cells in Autoimmunity
por: Hopp, Ann-Katrin, et al.
Publicado: (2014)

Functionally Competent, PD-1(+) CD8(+) Trm Cells Populate the Brain Following Local Antigen Encounter
por: Schøller, Amalie Skak, et al.
Publicado: (2021)

Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands
por: Garman, Bradley, et al.
Publicado: (2023)

Beyond Type 1 Regulatory T Cells: Co-expression of LAG3 and CD49b in IL-10-Producing T Cell Lineages
por: Huang, Weishan, et al.
Publicado: (2018)

CD4(+)CD25(+)LAG3(+) T Cells With a Feature of Th17 Cells Associated With Systemic Lupus Erythematosus Disease Activity
por: Kato, Rika, et al.
Publicado: (2019)

Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer
por: Shi, An-Ping, et al.
Publicado: (2022)

SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells
por: Ponce, Laia Pascual, et al.
Publicado: (2017)

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
por: Pesce, Silvia, et al.
Publicado: (2019)

Interleukin-7 Modulates Anti-Tumor CD8(+) T Cell Responses via Its Action on Host Cells
por: Deiser, Katrin, et al.
Publicado: (2016)

Targeting CD157 in AML using a novel, Fc-engineered antibody construct
por: Krupka, Christina, et al.
Publicado: (2017)

Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples
por: Liu, Qiang, et al.
Publicado: (2021)

Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells
por: Robbins, Yvette, et al.
Publicado: (2020)

Early Growth Response Gene 2-Expressing CD4(+)LAG3(+) Regulatory T Cells: The Therapeutic Potential for Treating Autoimmune Diseases
por: Okamura, Tomohisa, et al.
Publicado: (2018)

LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures
por: Gestermann, Nicolas, et al.
Publicado: (2020)

Chimeric Antigen Receptor–Modified T Cells and T Cell–Engaging Bispecific Antibodies: Different Tools for the Same Job
por: Schwerdtfeger, Melanie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_64l1kh80mue8fvhn8ihh9bb0n7